Dr. Lal Path Labs Ltd. — Investor Meet, 06-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs reported Q4 FY26 revenue of Rs. 703 Cr (+16.6%) and FY26 revenue of Rs. 2,763 Cr (+12.2%). FY26 PAT stood at Rs. 510 Cr (18.4% margin), with patient volume growth at 5.3%. Management projects early to mid-teens revenue growth for FY27, aiming for 27-28% EBITDA margins, driven by ongoing investments. The company expanded its network by adding 14 labs and over 1,100 collection centers, and acquired Shahbazkers Diagnostics for Rs. 20 Cr to bolster Mumbai operations. Strategic focus includes high-end diagnostics, preventive health (Swasthfit contributed 27% of FY26 revenue), and new initiatives like Sovaaka. Management is confident in sustained growth via network expansion and strategic investments.